The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
ALK in Lung Cancer: Past, Present, and Future
Open accessAbstract
In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non–small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Food and Drug Administration approval in 2011. Although crizotinib induces remissions and extends the lives of patients, cures are not achieved as resistance to therapy develops. In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-positive lung cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“By comparison, standard single-agent chemotherapies in previously treated patients with advanced unselected NSCLC had traditionally led to response rates of 10% or less and a median PFS of 2 to 3 months.(18,19) Similar impressive clinical activity has been observed in an ongoing global phase II study of crizotinib in…”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationAnaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cited by
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citationGridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,083
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Costa, D. B., Shaw, A. T., Ou, S.-H. I., Solomon, B. J., Riely, G. J., Ahn, M.-J., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 599
Self-citationRegulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Targeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 522
Self-citationThird-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Therapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M. C., Wiesner, T., Rosen, N., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 494
Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.010 · Cited by 471
Self-citationTargeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon, A., Cappuzzo, F., Ou, S.-H. I., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.014 · Cited by 389
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
The role of the ALK receptor in cancer biology
Hallberg, B., & Palmer, R. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw301 · Cited by 377
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2294 · Cited by 349
Self-citationCrizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Kazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
Du, X., Shao, Y., Qin, H., Tai, Y., & Gao, H. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12613 · Cited by 275
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Zou, H. Y., Li, Q., Engstrom, L. D., West, M., Appleman, V., Wong, K. A., McTigue, M., Deng, Y.-L., Liu, W., Brooun, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420785112 · Cited by 267
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 263
Self-citationBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno, T., Nakaoku, T., Tsuta, K., Tsuchihara, K., Matsumoto, S., Yoh, K., & Goto, K. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2014.11.11 · Cited by 263
Prognostic Value of Sarcopenia in Lung Cancer
Yang, M., Shen, Y., Tan, L., & Li, W. (2019) · Chest · doi:10.1016/j.chest.2019.04.115 · Cited by 258
Ilie, M., Hofman, V., Dietel, M., Soria, J.-C., & Hofman, P. (2016) · Virchows Archiv · doi:10.1007/s00428-016-1910-4 · Cited by 257
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer
Asada, K., Kobayashi, K., Joutard, S., Tubaki, M., Takahashi, S., Takasawa, K., Komatsu, M., Kaneko, S., Sese, J., & Hamamoto, R. (2020) · Biomolecules · doi:10.3390/biom10040524 · Cited by 67
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Amin, A. D., Rajan, S. S., Groysman, M. J., Pongtornpipat, P., & schatz, J. H. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29326 · Cited by 25
Metadata
- Authors
- Shaw, A. T., & Engelman, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-03-10
- Volume
- 31
- Issue
- 8
- Pages
- 1105-1111
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106915761
- Cited by
- 461
- References
- 46
- FWCI
- 43.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.